表紙
市場調査レポート

ポイントオブケア血液凝固検査の世界市場

Point of Care Coagulation Testing: World Market 2013-2023

発行 Visiongain Ltd 商品コード 269886
出版日 ページ情報 英文 106 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.04円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
ポイントオブケア血液凝固検査の世界市場 Point of Care Coagulation Testing: World Market 2013-2023
出版日: 2013年04月26日 ページ情報: 英文 106 Pages
概要

2011年ポイントオブケア(POC)診断市場全体の規模は価額にして138億ドル。前年から一桁とはいえ高水準の伸び率を示しています。広範かつ成熟した市場であるにもかかわらず、いくつかの疾患の世界的拡大からおよび老齢化が大きな要因となって今後10年間はこの成長が続くものと見られます。このうち、同年のポイントオブケア血液凝固検査世界市場は、検査キットや器具を含めて、10億ドル規模。これが2017年には18億ドルに達する見通しです。

当レポートでは、産業エキスパートへの克明な直接取材報告をまじえ、2013-2023年の期間にわたるポイントオブケア血液凝固検査世界市場の将来性を探る最新の市場調査情報をまとめ、概略以下の構成でお届けします。

第1章 エグゼクティブサマリー

  • ポイントオブケア血液凝固検査市場レビュー
  • レポートの狙い、対象範囲、形式
  • 各章の概要
  • 調査・分析方法

第2章 体外診断とポイントオブケア診断についてのイントロダクション

  • 体外診断(IVT)検査とは
  • 体外診断の分類:欧州分析機器製造業協会連合会(EDMA)分類
    • 臨床化学
    • 免疫化学
    • 血液学
    • 微生物学
    • 遺伝子検査
  • ポイントオブケア診断
  • 体外診断およびポイントオブケア診断市場の規制

第3章 ポイントオブケア診断市場

  • ポイントオブケア診断市場
  • 血糖検査はPOC市場売上中最大の貢献度
  • 自己検査 - POC市場売上における送達ポイント別で最大のセグメント
  • ポイントオブケア診断市場予測
  • ポイントオブケア診断市場予測

第4章 ポイントオブケア血液凝固検査市場

  • ポイントオブケア血液凝固検査市場
  • ポイントオブケア血液凝固検査市場で入手できる製品
  • 2017年まで順調な成長が見込まれるポイントオブケア血液凝固検査
  • ポイントオブケア血液凝固検査市場予測
  • 成長推進要因

第5章 プロトロンビン時間・国際標準化比率(PT/INR)検査市場

  • 患者自己検査は最小も最速成長セグメント
  • PT/INRポイントオブケア検査市場全体に検査ストリップが占める割合は85%
  • PT/INR検査市場予測

第6章 抗凝固薬市場

  • 抗凝固薬
    • ヘパリン
    • ビタミンK抗凝固薬
    • 直接トロンビン阻害薬
    • 直接ファクターXa阻害薬
  • 抗凝固薬市場
  • 抗凝固薬市場予測
  • ビタミンK抗凝固薬
    • ビタミンK抗凝固薬市場
    • ビタミンK抗凝固薬 - 市場セクター予測

第7章 主要国のポイントオブケアPT/INR検査市場

  • 最大のポイントオブケアPT/INR検査市場は米国
  • 血液凝固自己モニタリング:医療報酬の現況
  • 米国市場
  • 欧州市場
    • ドイツ
    • 英国
    • フランス
    • その他の国々
  • その他の地域市場
    • 日本
    • インド

第8章 ポイントオブケアPT/INR検査市場の主要企業

第9章 開発段階にある製品

第10章 ポイントオブケア凝固検査市場SWOT分析

第11章 エキスパート所見

第12章 結論

  • ポイントオブケア凝固検査の概要
  • ポイントオブケア凝固検査導入の商業的推進要因
  • ポイントオブケア凝固検査導入の商業的抑制要因
  • ポイントオブケア凝固検査市場の発展
  • 将来見通しと結びの言葉

図表一覧

目次

In 2011, the global point of care diagnostics market was worth $13.8bn, with high single-digit growth from the year before. Despite being a vast and mature market, there are number of sectors likely to experience fast growth during the next 10 years. Much of this growth is linked to the prevalence of a number of diseases worldwide, as well as an aging population. The preference for at home testing and its convenience will continue to drive the point of care diagnostics market.

The point of care coagulation market is one of the largest sectors in the global point of care industry. In 2011, the global POC coagulation testing market (including the sales of kits and instruments) was valued at $1.0bn. Total sales in this market are predicted to reach $1.8bn in 2017. PT/INR testing was the largest segment in the POC coagulation testing market with sales of $0.6bn in 2011.

For the past several years, four companies - Roche, International Technidyne Corporation (ITC), Abbott, and Alere - have dominated the POC PT/INR testing market. The devices currently available in the market are able to meet demand. However, there is need for improvement in technology to attract more physicians and patients to use this testing. Most of the testing for patients on anticoagulant warfarin is currently conducted in laboratories. Such patients need regular monitoring. The use of POC tests can help save a lot of time and money spent on unwanted complications arising from the use of the drug without monitoring.

The primary driver for growth will be the increasing use of anticoagulant therapy and higher adoption of self-testing kits for use at home. Anticoagulant drugs are commonly used for the treatment of thrombosis and associated disorders, including stroke, myocardial infarction and pulmonary embolism. The global epidemic of heart attack and stroke is predicted to continue and indeed worsen, from 2011 to 2023. However, market growth will slow down beyond 2017, with the launch of new oral anticoagulants in the market to replace warfarin.

Point of Care Coagulation Testing: World Market 2013-2023 provides an in-depth analysis of this segment. The report uses a wealth of research tools - including market forecasting, qualitative analyses, probing interviews with industry experts, literature searches and use of commercial databases. The report is packed with original data in tables, charts and other formats.

Why you should buy Point of Care Coagulation Testing: World Market 2013-2023

In this report, you will receive the following benefits:

  • You will receive a comprehensive analysis of prospects in the point of care coagulation testing market as a whole from 2011 to 2023, including predicted market sizes, growth rates and other metrics for leading sectors
  • You will receive an overall forecast for the point of care market and point of care coagulation testing market from 2012 to 2023, as well as that for the PT/INR market, with discussions and other supporting information
  • You will receive an overall forecast for the anticoagulant drug market from 2012 to 2023, with comprehensive discussions and other supporting information
  • You will discover revenue forecasts to 2023 for leading national markets (US, Europe, and Rest of the World), seeing growth trends
  • You will receive analysis of leading companies in the point of care coagulation testing market
  • You will find out where the market is heading - both technologically and commercially - from 2012 onwards
  • You will discover the drivers, restraints, competition and opportunities influencing the point of care coagulation testing market
  • You will identify where new opportunities lie in these sectors, with commercial opportunities and challenges discussed
  • You will view opinions from our industry survey, receiving full interview transcripts.

Table of Contents

1. Executive Summary

  • 1.1 The Point of Care (POC) Coagulation Testing Market Review
  • 1.2 Aims, Scope and Format of the Report
    • 1.2.1 Chapter Outlines
  • 1.3 Research and Analysis Methods

2. Introduction to In-Vitro Diagnostics and POC Diagnostics

  • 2.1 What are In Vitro Diagnostic (IVD) Tests?
  • 2.2 Classifying IVD: EDMA Classification
    • 2.2.1 Clinical Chemistry
    • 2.2.2 Immunochemistry
    • 2.2.3 Haematology
    • 2.2.4 Microbiology
    • 2.2.5 Genetic Testing
  • 2.3 Point of Care (POC) Diagnostics
    • 2.3.1 Advantages and Disadvantages of POC Diagnostics
  • 2.4 Regulation of the IVD and POC Market
    • 2.4.1 FDA Classifications
    • 2.4.2 FDA and CLIA Regulation of IVD and POC Tests
    • 2.4.3 Regulation of IVD/POC Diagnostics in the EU

3. The Point of Care Diagnostics Market, 2011-2023

  • 3.1 Point of Care Diagnostics Market, 2011
  • 3.2 Blood Glucose Testing is the Largest Contributor to the POC Market Sales
  • 3.3 Self Testing - Largest Segment in the POC Market by the Point of Delivery, 2011
  • 3.4 Point of Care Diagnostics Market Forecast, 2012-2017
  • 3.5 Point of Care Diagnostics Market Forecast, 2017-2023

4. POC Coagulation Testing Market, 2011-2023

  • 4.1 The POC Coagulation Testing Market in 2011
    • 4.1.1 PT/INR Monitoring is the Largest Segment in the POC Coagulation Testing Market
    • 4.1.2 Roche Dominates the POC Coagulation Testing Market with CoaguChek XS System
  • 4.2 Products Available in the POC Coagulation Testing Market, 2013
  • 4.3 POC Coagulation Testing Will Witness Strong Growth to 2017
  • 4.4 POC Coagulation Testing Market Forecast, 2017-2023
  • 4.5 Drivers for Growth

5. The PT/INR Testing Market, 2011-2023

  • 5.1 Patient Self Testing is the Smallest, But Fastest Growing Segment
  • 5.2 Test Strips Generate 85% of the Sales in the PT/INR POC Testing Market
  • 5.3 PT/INR Testing Market Forecast, 2012-2023

6. Anticoagulant Drugs Market, 2011-2023

  • 6.1 Anticoagulants
    • 6.1.1 Heparins
    • 6.1.2 Vitamin K Antagonists
    • 6.1.3 Direct Thrombin Inhibitors
    • 6.1.4 Direct Factor Xa Inhibitors
  • 6.2 The Anticoagulants Market in 2011
  • 6.3 Anticoagulants Market Forecast, 2012-2023
  • 6.4 Vitamin K Antagonists
    • 6.4.1 The Vitamin K Antagonists Market in 2011
    • 6.4.2 Vitamin K Antagonists: Market Sector Forecast, 2012-2023

7. Leading National Markets for POC PT/INR Testing, 2011-2023

  • 7.1 The US is the Largest Market for POC PT/INR Testing
  • 7.2 Coagulation Self-Monitoring: Reimbursement Status
  • 7.3 The US Market
  • 7.4 The European Market
    • 7.4.1 Germany
    • 7.4.2 The UK
    • 7.4.3 France
    • 7.4.4 Other European Countries
  • 7.5 Rest of the World Markets
    • 7.5.1 Japanese Market
    • 7.5.2 Indian Market

8. Leading Companies in the POC PT/INR Testing Market

  • 8.1 Four Companies Dominate the POC PT/INR Testing Market
  • 8.2 Company Profiles
    • 8.2.1 Roche
      • 8.2.1.1 Global Presence
      • 8.2.1.2 Sales and Recent Performance Analysis
      • 8.2.1.3 Roche Diagnostics
      • 8.2.1.4 Growing Portfolio of Coagulation Testing Products
      • 8.2.1.5 Recent M&A Activity and Strategic Collaborations
    • 8.2.2 Abbott Laboratories
      • 8.2.2.1 Sales and Recent Performance Analysis
      • 8.2.2.2 Abbott: Diagnostics Segment
      • 8.2.2.3 Point of Care Diagnostics Products
      • 8.2.2.4 Abbott IVD Segment: Strengths & Challenges
      • 8.2.2.5 Abbott Diagnostics Historical Revenues, 2009-2011
      • 8.2.2.6 Recent M&A Activity and Strategic Collaborations
        • 8.2.2.6.1 Collaboration with GSK
        • 8.2.2.6.2 Collaboration with Merck
        • 8.2.2.6.3 Acquisition of STARLIMS Technologies
        • 8.2.2.6.4 Acquisition of Ibis Biosciences
    • 8.2.3 International Technidyne Corporation (ITC)
      • 8.2.3.1 Overview
      • 8.2.3.2 Products
      • 8.2.3.3 Blood Coagulation Monitor Devices

9. Products in the Pipeline

  • 9.1 POC Coagulation Test Systems in Development
    • 9.1.1 Portable Coagulation Monitor, Entegrion
    • 9.1.2 Blood Coagulation Monitor, Bio-AMD
    • 9.1.3 Siemens-Universal Biosensors Collaboration

10. SWOT Analysis of the POC Coagulation Testing Market, 2013-2023

  • 10.1 Strengths and Weaknesses of the Sector
    • 10.1.1 Thrombotic Diseases: Management Rather Than Cure
    • 10.1.2 Better Patient and Disease Management
    • 10.1.3 Warfarin Has Been the Anticoagulant of Choice for More Than 50 Years
    • 10.1.4 Availability of Several POC Devices
    • 10.1.5 Availability of International Guidelines for Self-Monitoring
    • 10.1.6 The Cost of POC Tests
    • 10.1.7 Educating the End-Users
  • 10.2 Opportunities and Threats
    • 10.2.1 Consistent Technological Developments
    • 10.2.2 Rising Disease Prevalence
    • 10.2.3 Launch of New Class of Anticoagulants
    • 10.2.4 Expansion into Developing National Markets and Lifestyle Diseases Will Drive the Market
    • 10.2.5 High-Entry Barriers in the POC Blood Coagulation Testing Market
    • 10.2.6 Medical Device Excise Tax: A Threat to the OEMs

11. Expert Opinion

  • 11.1 Interview with Dr Frank Peacock, Professor, Associate Chair and Research Director, Baylor College of Medicine, Houston, Texas
    • 11.1.1 Warfarin vs Novel Oral Anticoagulants
    • 11.1.2 The Unmet Needs of the Market
    • 11.1.3 The R&D Pipeline
    • 11.1.4 Key Market Drivers and Restraints
  • 11.2 Interview with Dr Jonathan L. Halperin, Professor of Medicine, Director of Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center, New York
    • 11.2.1 Unmet Needs
    • 11.2.2 New Findings
    • 11.2.3 Warfarin Replacement
    • 11.2.4 Areas Demanding Attention
    • 11.2.5 Key Market Restraints

12. Conclusions

  • 12.1 Overview of Point of Care Coagulation Testing
  • 12.2 Commercial Drivers for the Adoption of POC Coagulation Tests
  • 12.3 Commercial Restraints in the POC Coagulation Testing Market
  • 12.4 Growth of POC Coagulation Testing Market from 2013 to 2023
  • 12.5 Future Outlook and Concluding Remarks

List of Tables

  • Table 2.1 Advantages and Disadvantages of POC Diagnostics
  • Table 3.1 POC Market by Leading Segments, Sales ($bn) and Market Share (%), 2011
  • Table 3.2 Self Testing & Professional Testing in the POC Market ($bn), 2011
  • Table 3.3 World POC Diagnostics Market Forecast ($bn), 2011-2017
  • Table 3.4 World POC Diagnostics Market Forecast ($bn), 2017-2023
  • Table 4.1 Global POC Coagulation Testing Market ($m) by Marker, 2011
  • Table 4.2 Global POC Coagulation Testing Market ($m) by Leading Companies, 2011
  • Table 4.3 List of Some Products in the POC Coagulation Testing Market, 2013
  • Table 4.4 The POC Coagulation Testing Market Forecast ($bn), 2011-2017
  • Table 4.5 The POC Coagulation Testing Market Forecast ($bn), 2017-2023
  • Table 5.1 PT/INR POC Testing Market ($m) by Point of Use, 2011
  • Table 5.2 The Price of Some POC PT/INR Testing Systems, 2012
  • Table 5.3 PT/INR POC Testing Market ($m) by Components, 2011
  • Table 5.4 The PT/INR Testing Market Forecast ($m), 2011-2017
  • Table 5.5 The PT/INR Testing Market Forecast ($m), 2017-2023
  • Table 6.1 Anticoagulant Drug Market: Revenues ($m) by Class, 2011
  • Table 6.2 Anticoagulant Classes: Revenue Forecasts ($m), 2011-2017
  • Table 6.3 Anticoagulant Classes: Revenue Forecasts ($m), 2018-2023
  • Table 6.4 Vitamin K Antagonists: Market Sector Forecast ($m), 2011-2023
  • Table 6.5 The Vitamin K Antagonist Market: Drivers and Restraints, 2013-2023
  • Table 7.1 PT/INR POC Testing Market ($m) by Region, 2011
  • Table 7.2 Leading National PT/INR Testing Market Forecast ($m), 2011-2023
  • Table 7.3 Reimbursement for Coagulation Self-Monitoring In the US and Some European Countries, 2011
  • Table 7.4 The US PT/INR Testing Market Forecast ($m), 2011-2023
  • Table 7.5 The European PT/INR Testing Market Forecast ($m), 2011-2023
  • Table 7.6 Rest of the World PT/INR Testing Market Forecast ($m), 2011-2023
  • Table 8.1 POC PT/INR Testing Market ($m) by Companies, 2011
  • Table 8.2 Roche: Key Facts, 2013
  • Table 8.3 Roche: Revenue ($bn) and Revenue Shares (%) by Sector, 2011
  • Table 8.4 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%), by Region, 2011
  • Table 8.5 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%) by Sector, 2011
  • Table 8.6 Abbott: Key Facts, 2013
  • Table 8.7 Abbott: Net Sales ($bn) & Net Sales Shares (%), By Business Segment, 2011
  • Table 8.8 Abbott: Net Sales ($bn) and Net Sales Shares (%), by Geographical Region, 2011
  • Table 8.9 Abbott Diagnostics: Net Sales ($bn) and Net Sales Shares by Sub-Segment, 2011
  • Table 8.10 Abbott: Diagnostics Net Sales ($bn), 2009-2011
  • Table 9.1 List of Some POC Coagulation Tests Under Development, 2011
  • Table 10.1 SWOT Analysis of the POC Coagulation Testing Market

List of Figures

  • Figure 3.1 Market Shares (%) of Leading Segments in the POC Diagnostics Market, 2011
  • Figure 3.2 Market Share (%) of Self Testing & Professional Testing in the POC Market, 2011
  • Figure 3.3 World POC Diagnostics Market Forecast ($bn), 2011-2017
  • Figure 3.4 World POC Diagnostics Market Forecast ($bn), 2017-2023
  • Figure 4.1 Market Share (%) of POC Coagulation Testing Market by Type of Marker, 2011
  • Figure 4.2 Market Share (%) of Roche in the POC Coagulation Testing Market, 2011
  • Figure 4.3 The POC Coagulation Testing Market Forecast ($bn), 2011-2017
  • Figure 4.4 The POC Coagulation Testing Market Forecast ($bn), 2017-2023
  • Figure 5.1 Market Share (%) of the PT/INR POC Testing Market by Point of Use, 2011
  • Figure 5.2 Market Share (%) of Meters and Strips in the PT/INR POC Testing Market, 2011
  • Figure 5.3 The PT/INR Testing Market Forecast ($m), 2011-2017
  • Figure 5.4 The PT/INR Testing Market Forecast ($m), 2017-2023
  • Figure 6.1 Anticoagulant Drugs: Market Sector Shares (%), 2011
  • Figure 6.2 Anticoagulant Drugs: Overall Sector Forecast ($m), 2011-2023
  • Figure 6.3 Anticoagulant Drugs: Market Sector Shares (%), 2023
  • Figure 6.4 Vitamin K Antagonists: Market Sector Forecast ($m), 2011-2023
  • Figure 7.1 Regional Market Share (%) of the PT/INR POC Testing Market, 2011
  • Figure 7.2 The US PT/INR Testing Market Forecast ($m), 2011-2023
  • Figure 7.3 The European PT/INR Testing Market Forecast ($m), 2011-2023
  • Figure 7.4 Rest of the World PT/INR Testing Market Forecast ($m), 2011-2023
  • Figure 8.1 Sales ($m) of Leading Companies in the POC PT/INR Testing Market, 2011
  • Figure 8.2 Market Share (%) of Leading Companies in the POC PT/INR Testing Market, 2011
  • Figure 8.3 Roche: Revenues ($bn) by Sector, 2011
  • Figure 8.4 Roche: Revenue Shares (%) by Industry Area, 2011
  • Figure 8.5 Roche Diagnostics: Revenue Shares (%) by Region, 2011
  • Figure 8.6 Roche Diagnostics: Revenues ($bn) by Sector, 2011
  • Figure 8.7 Roche Diagnostics: Revenue Share (%) by Sector, 2011
  • Figure 8.8 Abbott: Net Sales ($bn) By Business Segment, 2011
  • Figure 8.9 Abbott: Net Sales Shares (%), By Business Segment, 2011
  • Figure 8.10 Abbott Historical Performance: Net Sales ($bn), Net Income ($bn), Profit Margin (%), 2007-2011
  • Figure 8.11 Abbott: Net Sales ($bn) by Region, 2011
  • Figure 8.12 Abbott: Net Sales Shares (%) by Region, 2011
  • Figure 8.13 Abbott Diagnostics: Net Sales ($bn) by Sub-Segment, 2011
  • Figure 8.14 Abbott Diagnostics: Net Sales Shares (%) by Sub-Segment, 2011
  • Figure 8.15 Abbott Diagnostics: Historical Margin (%) Improvement, 2007-2011

Companies Listed

  • Abbott
  • AbbVie
  • Alere
  • AntiCoagulation Europe
  • AntiCoagulation Self-Monitoring Alliance (ACSMA)
  • Atrial Fibrillation Association
  • Barr Pharmaceuticals
  • Bayer
  • Baylor College of Medicine [US]
  • Bio-AMD
  • Boehringer Ingelheim
  • Centers for Device and Radiological Health (CDRH) [US]
  • Centers for Disease Control and Prevention (CDC) [US]
  • Centers for Medicare & Medicaid Services (CMS) [US]
  • Children's Heart Federation
  • Chugai Pharmaceuticals
  • CoaguSense
  • College of American Pathologists
  • EIDIA
  • Eisai
  • Entegrion
  • European Commission
  • European Diagnostics Manufacturers Association (EDMA)
  • Food and Drug Administration (FDA) [US]
  • Genentech
  • GlaxoSmithKline
  • Helena Laboratories
  • Ibis Biosciences
  • Instrumentation Laboratory
  • International Self-Monitoring Association of Oral Anticoagulated Patients (ISMAAP)
  • International Technidyne Corporation
  • La Federación Espa&ntilede;ola de Asociaciones de Anticoagulados (FEASAN)
  • Mechanical Heart Valve Support Group
  • Medtronic
  • Merck
  • Ministry of Health, Labor and Welfare (MHLW) [Japan]
  • Mount Sinai School of Medicine
  • National Health Service (NHS) [UK]
  • Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
  • Portola Pharmaceuticals
  • QuickMedical
  • Roche
  • Siemens
  • STARLIMS Technologies
  • Suyog Diagnostics
  • Teva
  • Thermo Cardiosystems
  • Thermo Electron Corporation
  • Thoratec Corporation
  • Transasia Bio-Medicals
  • Universal Biosensor (UBI)
  • US Department of Defense (DoD)
  • Ventana
  • Warburg Pincus
  • Werfen Group
  • World Health Organization (WHO)
Back to Top